RG7287 is an activating antibody inhibitor targeting human CDCP1. RG7287 prevents the loss of contact inhibition caused by the co-transformation of NIH3T3 cells with CDCP1 and Src in focus formation assays. RG7287 inhibits tumor cell proliferation and leads to a significant reduction in CDCP1 levels[1].
